Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LQDA | LIQUIDIA CORP | $61.97 | $18.39 | 236.91% | 258.21x | 18.69x | 18.93x | 50.75x | 1.22x | $41.15M | 0.76% | $108.58M | 1.23 | $5.47B | 102.10 | ||
| CORT | CORCEPT THERAPEUTICS INC | $59.69 | $18.96 | 214.84% | 129.76x | 114.00x | 8.11x | 10.04x | 1.22x | $119.79M | 1.92% | $637.99M | 6.11 | $6.31B | -918.83 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $300.51 | $94.79 | 217.04% | 68.92x | 40.75x | 9.32x | 37.31x | 1.42x | $641.34M | 1.61% | $1.08B | 8.09 | $41.38B | 44.76 | ||
| HALO | HALOZYME THERAPEUTICS INC | $68.52 | $70.94 | -3.42% | 23.15x | 8.27x | 5.37x | 37.00x | 0.42x | $667.65M | 8.25% | $219.64M | 1.86 | $9.96B | 15.97 | ||
| KRYS | KRYSTAL BIOTECH INC | $304.23 | $96.24 | 216.11% | 39.26x | 37.63x | 21.35x | 7.02x | 1.86x | $237.38M | 2.66% | $1.28B | 43.59 | $8.48B | 39.62 | ||
| ADMA | ADMA BIOLOGICS INC | $8.46 | $10.55 | -19.80% | 12.26x | 8.52x | 3.92x | 5.02x | 0.42x | $107.90M | 5.40% | $390.33M | 1.65 | $2.02B | 9.12 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $54.10 | $41.08 | 31.69% | 38.64x | 13.62x | 3.21x | 1.68x | 0.54x | $767.06M | 7.37% | $6.21B | 32.27 | $8.81B | 18.27 | ||
| VCEL | VERICEL CORP | $35.15 | $9.19 | 282.39% | 81.74x | 72.91x | 6.11x | 5.04x | 1.72x | $47.49M | 2.66% | $356.23M | 7.02 | $1.78B | 44.05 | ||
| OMER | OMEROS CORP | $11.96 | $15.62 | -23.43% | 9.20x | -31.41x | 86.67x | -13.67x | 0.46x | -$94.78M | -11.02% | -$63.33M | -0.88 | $1.17B | 12.99 | ||
| RPRX | ROYALTY PHARMA PLC | $53.55 | $40.13 | 33.45% | 28.04x | 10.04x | 9.58x | 3.10x | 0.60x | $2.34B | 10.01% | $9.94B | 22.75 | $39.21B | 33.70 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $10.49 | $16.36 | -35.88% | 5.12x | 22.32x | 5.01x | 3.01x | 0.65x | $56.42M | 9.21% | $205.80M | 3.52 | $525.67M | 3.64 | ||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $6.38 | $2.84 | 124.54% | 91.14x | 53.39x | 3.46x | 84.66x | 0.87x | $47.52M | 4.37% | $13.01M | 0.08 | $1.25B | 23.36 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $222.18 | $96.27 | 130.78% | 28.12x | 24.65x | 16.09x | 4.46x | 1.38x | $122.22M | 2.77% | $997.32M | 50.16 | $4.79B | 21.24 | ||
| ASND | ASCENDIS PHARMA A | $247.51 | $84.28 | 193.66% | 26.23x | 19.93x | 15.09x | 26.78x | 2.44x | $52.94M | 0.34% | $574.09M | 9.24 | $15.75B | 168.94 | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $239.40 | $49.05 | 388.12% | 509.36x | 9.27x | 3.34x | 3.31x | 1.74x | $1.30B | 8.76% | $4.53B | 73.22 | $18.58B | 27.52 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $53.65 | $15.99 | 235.46% | 54.74x | 48.64x | 5.44x | 6.81x | 1.68x | $164.23M | 4.00% | $605.69M | 7.92 | $3.95B | 35.40 | ||
| SPRO | SPERO THERAPEUTICS INC | $2.69 | $5.77 | -53.38% | 9.96x | 3.94x | 2.52x | 2.94x | 0.21x | $7.24M | 4.68% | $52.93M | 0.92 | $102.10M | 6.59 | ||
| TECH | BIO-TECHNE CORP | $47.37 | $15.48 | 206.00% | 66.72x | 24.09x | 6.12x | 3.56x | 1.37x | $269.60M | 3.64% | $2.09B | 13.34 | $7.50B | 29.29 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $30.49 | $36.07 | -15.48% | 12.05x | 8.31x | 1.96x | 1.94x | 0.45x | $341.79M | 19.39% | $910.35M | 15.75 | $1.33B | 5.63 | ||
| TGTX | TG THERAPEUTICS INC | $39.24 | $18.73 | 109.46% | 12.19x | 26.14x | 8.09x | 10.30x | 7.97x | -$14.19M | -0.25% | $583.13M | 4.04 | $6.32B | 42.10 | ||
| UTHR | UNITED THERAPEUTICS CORP | $565.87 | $248.86 | 127.39% | 19.33x | 19.47x | 7.77x | 4.07x | 2.04x | $1.02B | 4.13% | $5.90B | 135.66 | $22.74B | 13.27 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $3.79 | $2.47 | 53.16% | 15.79x | 16.02x | 2.32x | 3.67x | 1.07x | $4.11M | 1.35% | $82.33M | 1.03 | $237.88M | 11.20 | ||
| EXEL | EXELIXIS INC | $49.65 | $31.03 | 59.99% | 15.91x | 15.07x | 5.40x | 6.45x | 1.16x | $917.69M | 7.15% | $1.94B | 7.49 | $12.42B | 11.76 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $31.28 | $14.99 | 108.69% | 17.28x | 16.26x | 6.41x | 3.78x | 1.96x | $208.13M | 5.44% | $1.01B | 8.28 | $3.07B | 9.18 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $642.59 | $445.57 | 44.22% | 15.10x | 13.59x | 4.48x | 2.14x | 0.99x | $4.11B | 6.15% | $31.42B | 302.15 | $67.11B | 11.68 | ||
| MDXG | MIMEDX GROUP INC | $3.61 | $1.57 | 129.78% | 17.19x | -50.56x | 1.38x | 2.21x | 2.67x | $69.36M | 12.94% | $242.94M | 1.64 | $395.52M | 7.26 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $433.54 | $170.77 | 153.88% | 25.49x | 22.16x | 9.02x | 5.68x | 1.82x | $3.71B | 3.37% | $19.36B | 76.20 | $106.53B | 19.75 | ||
| VCYT | VERACYTE INC | $45.19 | $12.41 | 264.03% | 40.71x | 40.15x | 6.63x | 2.68x | 2.34x | $155.34M | 4.32% | $1.34B | 16.90 | $3.38B | 29.38 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $2.03 | $1.75 | 15.86% | 10.68x | 9.35x | 2.12x | 2.43x | 0.92x | $13.00M | 8.03% | $67.23M | 0.84 | $130.33M | 5.84 | ||
| SRPT | SAREPTA THERAPEUTICS INC | $16.96 | $4.63 | 266.42% | 28.27x | 4.87x | 0.82x | 1.19x | 3.96x | $109.24M | 6.13% | $1.51B | 14.34 | $2.36B | 28.56 | ||
| INCY | INCYTE CORP | $97.41 | $66.55 | 46.38% | 13.36x | 12.37x | 3.62x | 3.46x | 1.18x | $1.45B | 7.47% | $5.62B | 28.21 | $16.03B | 8.57 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.